BAJAJ BROKING

Notification close image
No new Notification messages
card image
Oswal Pumps IPO is Open!
Apply for the Oswal Pumps IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Jubilant Pharmova Approves API Business Slump Sale to Jubilant Biosys

Synopsis:

Jubilant Pharmova will transfer its API business to subsidiary Jubilant Biosys via a slump sale. The division recorded Rs.609 crore revenue in FY25. Jubilant Pharmova share price dropped 1.74% to Rs.1,125 post-announcement on the BSE..


Jubilant Pharmova Ltd announced on June 12 that its board has approved the sale and transfer of its active pharmaceutical ingredient (API) business to Jubilant Biosys Ltd, a wholly-owned subsidiary. The transaction will be executed as a slump sale and is expected to be completed by September 1, 2025, subject to regulatory and procedural approvals.

The sale marks a structural reshuffle within the group, aimed at streamlining operations by transferring the API vertical into a subsidiary focused on global drug discovery services.

Also read: DCM Shriram to Acquire Hindusthan Specialty Chemicals for Rs. 375 Crore

JUBILANT PHARMOVA LTD

Trade

1094.2-31.40 (-2.78 %)

Updated - 13 June 2025
1174.40day high
DAY HIGH
1060.00day low
DAY LOW
6466031
VOLUME (BSE)

Key Takeaways

  • API division revenue (FY25): Rs.609 crore (8.35% of consolidated revenue).

  • Net worth of API division: Rs.666.5 crore (10.68% of consolidated net worth).

  • Transfer mode: Slump sale, mainly through share issuance.

  • Completion timeline: On or before September 1, 2025.

  • Jubilant Pharmova share price: Closed at Rs.1,125, down 1.74%.

Also read: Genus Power: GIC Affiliate Plans Rs.650 Crore Stake Sale via Block Deal

Transaction Structure And Financial Basis

The deal qualifies as a related party transaction, as Jubilant Biosys is a wholly-owned subsidiary of Jubilant Pharmova. However, the company confirmed the transaction would occur on an arm’s length basis. The sale is not part of any Scheme of Arrangement, and hence Regulation 37A of SEBI Listing Regulations is not applicable.

The consideration will be determined based on the book value of assets and liabilities of the API division as of the appointed date.

Business Unit

Details

Division Transferred

API Business

Revenue (FY25)

Rs.609 crore

Net Worth (as of Mar 2025)

Rs.666.5 crore

Share of Consolidated Rev.

8.35%

Share of Consolidated NW

10.68%

Transfer Completion Date

By September 1, 2025

Strategic Purpose And Market Reaction

This internal restructuring allows Jubilant Pharmova to consolidate research-focused businesses under Jubilant Biosys while maintaining group control. By realigning the API vertical into a specialised unit, the company aims to boost operational focus across product categories.

Following the announcement, Jubilant Pharmova share price declined by Rs.19.90, or 1.74%, on the BSE, closing at Rs.1,125. Despite the dip, the move is viewed as part of the company’s broader strategy to enhance organisational efficiency and business alignment.

Jubilant Pharmova share price may continue to reflect short-term volatility until the completion of the transaction, depending on regulatory progress and integration outcomes.

Also read: Oil Prices Soar 11% as Israeli Strikes on Iran Trigger Supply Fears

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.4 App Rating

icon-with-text

4 Languages

icon-with-text

₹5100+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|